Bacterial vaginosis a "broad overview".
Bacterial vaginosis (BV) was first reported in 1995 by Gardner and Dukes, who described the unique clinical signs and symptoms and the distinctive nature of the vaginal discharge associated with it. They also described a "new" causative organism, which they named "Haemophilus vaginalis", subsequently renamed Gardnerella vaginalis. BV is currently the most prevalent cause of infectious vaginitis among women attending for genitourinary diseases. BV has a complex microbiology. Lactobacillus populations, which are usually dominant in healthy women, are replaced by a polymicrobial group of organisms that includes G. vaginalis, anaerobic Gram-negative rods such as Prevotella species, Peptostreptococcus species, Mycoplasma hominis, Ureaplasma urealyticum, and often Mobiluncus species. Anaerobic bacteria produce enzymes, aminopeptidases, that degrade protein and decarboxylases that convert amino acids and other compounds to amines. Those amines contribute to the signs and symptoms associated with the syndrome, raising the vaginal pH and producing a discharge odor. The excessive amounts of bacteria characteristic of the syndrome attach to epithelial cell surfaces, resulting in "clue cell". Nearly half the patients report no noticeable symptoms, but many develop a characteristic copious, malodorous discharge if untreated. Results from epidemiologic studies have associated BV with serious upper genital tract infections and adverse pregnancy outcome. In particular, the presence of BV in pregnant women increases the risk of preterm delivery, and evidence is now compelling that BV is a cause of preterm delivery. The interest in potential invasiveness of G. vaginalis has increased. However, virulence determinants have not been studied enough. The most important therapy includes clindamycin and metronidazole.
González Pedraza Avilés
A
A
C. S. C. Dr. José Castro Villagrana, Departamento de Medicina Familiar, Facultad de Medicina, UNAM, Instituto de Servicios de Salud del Distrito Federal, México D. F.
Ortíz Zaragoza
M C
MC
Irigoyen Coria
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016956:Burkholderia cepacia; D002648:Child; D002675:Child, Preschool; D005260:Female; D006194:Gardnerella vaginalis / Q000302:isolation & purification / Q000472:pathogenicity; D006801:Humans; D015994:Incidence; D007223:Infant; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D017904:Mobiluncus / Q000302:isolation & purification; D019535:Mycoplasma hominis / Q000302:isolation & purification; D007752:Obstetric Labor, Premature / Q000209:etiology; D009812:Odorants; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000453:epidemiology / Q000382:microbiology; D011256:Pregnancy Outcome; D015995:Prevalence; D018720:Prevotella / Q000302:isolation & purification; D016585:Vaginosis, Bacterial / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology* / Q000635:transmission; D014774:Virulence
D000900:Anti-Bacterial Agents; D008795:Metronidazole